Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MMV367 in Healthy Volunteers
NCT05507970Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MMV367 in Malaria (9 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Treatment-Emergent Adverse Events up to 6.5 weeks, Clinically Significant Physical Examination Findings up to 6.5 weeks and 7 more. Started Jul 2022; status: completed.
02
Drugs
MMV367
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT05507970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507970.